Completed PHASE1 INTERVENTIONAL 1-arm NCT01281852

Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer

A Limited Access Phase I Trial of Paclitaxel, Cisplatin and CTEP Supplied Agent ABT-888 (Veliparib) (NSC#737664) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix

Sponsor: NRG Oncology

Conditions Cervical Adenocarcinoma Cervical Adenosquamous Carcinoma Cervical Squamous Cell Carcinoma, Not Otherwise Specified Recurrent Cervical Carcinoma Stage IVB Cervical Cancer AJCC v6 and v7

Interventions Cisplatin Laboratory Biomarker Analysis Paclitaxel Veliparib

Updated 10 times since 2017 Last updated: Jul 17, 2019 Started: Mar 14, 2011 Primary completion: Feb 11, 2017 Completion: Feb 11, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Cervical Adenocarcinoma and Cervical Adenosquamous Carcinoma and is currently completed. NRG Oncology leads this study, which shows 10 recorded versions since 2011 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

10 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE1
Sep 2024 — Sep 2025 [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Aug 2019 — Jan 2021 [monthly]

Completed PHASE1

▶ Show 5 earlier versions

Jun 2018 — Aug 2019 [monthly]

Completed PHASE1
Aug 2017 — Jun 2018 [monthly]

Completed PHASE1

Phase: PHASE1_PHASE2 → PHASE1
May 2017 — Aug 2017 [monthly]

Completed PHASE1_PHASE2

Status: Active Not Recruiting → Completed
Feb 2017 — May 2017 [monthly]

Active Not Recruiting PHASE1_PHASE2
Jan 2017 — Feb 2017 [monthly]

Active Not Recruiting PHASE1_PHASE2

First recorded

Mar 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

NRG Oncology
National Cancer Institute (NCI)

Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Augusta, United States , Baltimore, United States , Charleston, United States , Charlottesville, United States , Chicago, United States , Cleveland, United States , Columbus, United States , Dallas, United States , Houston, United States , Iowa City, United States and 11 more locations